425: Waters Corporation and BD Announce Strategic Combination to Create Life Science and Diagnostics Leader

Waters Corporation and Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business, Augusta SpinCo Corporation, will combine to form a new life science and diagnostics leader, doubling the addressable market to $40 billion and enhancing financial outlook.

Summary

• Waters Corporation and Augusta SpinCo Corporation, a wholly-owned subsidiary of Becton, Dickinson and Company (BD) comprising its Biosciences and Diagnostic Solutions business, intend to combine.
• The transaction aims to create a life science and diagnostics leader focused on regulated, high-volume testing.
• The combination is expected to double Waters' addressable market to $40 billion.
• It will expand Waters' presence into fast-growing adjacencies including bioseparations, bioanalytical characterization, and multiplex diagnostics.
• The transaction is anticipated to be accretive to adjusted EPS in the first year post-closing and lead to enhanced growth and improved margins.
• BD will become a pure-play medical technology company, focusing on areas like biologic drug delivery, connected care, healthcare automation, and chronic disease solutions.
• The closing of the transaction is expected around the end of the first quarter of calendar year 2026.
• Until closing, both companies will continue to operate separately and independently.

Sentiment

Score: 9

Explanation: The document presents the proposed business combination in an overwhelmingly positive light, emphasizing strategic fit, significant market expansion, enhanced financial outlook (accretive EPS, improved growth and margins), and mutual benefits for both companies and their stakeholders. The tone is confident and forward-looking, with risks acknowledged but framed as standard cautionary statements.

Positives

• Diversification of the portfolio increases recurring revenue.
• Doubles the addressable market to $40 billion, focusing on regulated, high-volume end-markets.
• Accelerates expansion into fast-growing adjacencies: bioseparations, bioanalytical characterization, and multiplex diagnostics.
• Creates an industry-leading financial outlook with enhanced growth and improved margins.
• Expected to be accretive to adjusted EPS in the first year post-closing.
• Combines complementary strengths to serve important high-growth industries with significant unmet needs.
• Positions BD as a pure-play medical technology company at the forefront of healthcare growth trends.

Risks

• One or more closing conditions, including regulatory approvals or Waters stockholder approval, may not be satisfied or waived on a timely basis or at all.
• A governmental entity may prohibit, delay, or refuse to grant approval for the transaction, or require conditions, limitations, or restrictions.
• The proposed transaction may not be completed on the terms or in the timeframe expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company following completion of the transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including synergies, may occur due to delays or integration difficulties.
• Difficulties and delays may arise in the combined company achieving revenue and cost synergies.
• Inability to retain and hire key personnel could impact the combined company.
• Any event could occur that gives rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations in connection with the transaction may affect timing, occurrence, or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the transaction or combined entity.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs could affect outcomes.
• Actions by third parties, including government agencies, may impact the transaction.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty may arise in separating the business of SpinCo from other BD businesses.
• Disruption of management time from ongoing business operations due to the pendency of the transaction.
• Other effects of the pendency of the transaction on relationships with employees, customers, suppliers, or other counterparties.
• Additional risk factors detailed in Waters and BD's reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and other documents related to the transaction.

Future Outlook

The transaction is expected to close around the end of the first quarter of calendar year 2026. Integration planning will commence as the companies move toward closing, while both entities will continue to operate separately and independently until the transaction is complete. The combined company aims to build on existing successes and bring the benefits of pioneering science to more customers and patients.

Management Comments

• Udit Batra (Waters CEO & President): "Waters leadership has tremendous respect and admiration for BDs Biosciences & Diagnostic Solutions business, your history of innovation, and your world-class team."
• Udit Batra (Waters CEO & President): "Because of you, we are entering this new chapter from a position of strength."
• Udit Batra (Waters CEO & President): "There are three key reasons why this combination is such a strong strategic fit."
• Udit Batra (Waters CEO & President): "Waters has the playbook to unlock the full potential of BDs Biosciences & Diagnostics business."
• Udit Batra (Waters CEO & President): "I look forward to leading the combined company as we build on the success you have all been a part of."
• Tom Polen (BD Chairman, CEO & President): "I am thrilled about our intent to combine our Biosciences and Diagnostic Solutions business with Waters."
• Tom Polen (BD Chairman, CEO & President): "This transaction will be combining the complementary strengths of both Waters and BD to create a life science and diagnostics leader focused on regulated, high-volume testing."
• Tom Polen (BD Chairman, CEO & President): "Waters is the right fit for these great businesses and for our teams – both for the substantial value this will create for shareholders and because Waters is a great place for our teams to make an even more profound impact on global healthcare."
• Tom Polen (BD Chairman, CEO & President): "This transaction also represents a significant step forward in making BD a pure-play medical technology company."

Industry Context

This combination creates a leading entity in the life science and diagnostics sector, specifically targeting regulated, high-volume testing. It allows Waters to expand significantly into fast-growing adjacencies like bioseparations, bioanalytical characterization, and multiplex diagnostics. Concurrently, it enables BD to streamline its focus and become a pure-play medical technology company, concentrating on key growth trends such as biologic drug delivery, connected care, healthcare automation, and chronic disease solutions.

Legal Proceedings

• Risk of stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations that may affect the timing or occurrence of the transaction or result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Expected to create substantial value for shareholders of both Waters and BD.
• Employees (Associates/Teams): BD's Biosciences and Diagnostic Solutions teams will join Waters, a company that deeply values innovation, execution, and excellence, with new opportunities arising from the combination.
• Customers: Combined portfolios will offer unparalleled value with best-in-class products, addressing the needs of more customers and ultimately helping more patients.
• Partners: Expected to unlock value for partners.
• Creditors: Not explicitly mentioned, but the transaction involves financing and indebtedness, which could impact creditors.

Next Steps

• Begin integration planning as the companies move toward closing.
• Continue to operate separately and independently until the transaction closes.
• File relevant materials with the U.S. Securities and Exchange Commission (SEC), including a registration statement on Form S-4 by Waters and a registration statement on Form 10 by SpinCo.
• Communicate updates regarding the transaction to teams and stakeholders.
• Waters and BD will continue to focus on executing their respective business strategies and supporting customers until closing.

Key Dates

Recommendation

Keywords

Waters Corporation, Becton Dickinson, BD, Augusta SpinCo, Business Combination, Merger, Acquisition, Life Science, Diagnostics, Bioseparations, Bioanalytical Characterization, Multiplex Diagnostics, Regulated Testing, Healthcare Technology, SEC Filing